Targeting of the antivascular drug combretastatin to irradiated tumors results in tumor growth delay

Christopher B. Pattillo, Farid Sari-Sarraf, Ramakrishna Nallamothu, Bob Moore, George C. Wood, Mohammad F. Kiani

Research output: Contribution to journalArticle

48 Citations (Scopus)

Abstract

Purpose. The aim of the study is to evaluate the effects of targeting the antivascular drug combretastatin to irradiated mouse melanomas. Methods. Combretastatin was incorporated into liposomes with surfaces modified by the addition of cyclo(Arg-Gly-Asp-d-Phe-Cys) (RGD) to create an immunoliposome (IL). This addition of RGD allows the liposome to be preferentially targeted to αvβ3, an integrin up-regulated in the vasculature of irradiated tumors. C57BL mice bearing a transplanted B16-F10 melanoma were randomly assigned to one of the following treatment groups: untreated, a single dose of 5-Gy radiation (IR), IL (14.5 mg/kg of combretastatin), 5-Gy radiation plus IL, and a systemic administration of free drug (81.0 mg/kg of combretastatin). Results. In this transplanted tumor model, there was no significant increase in the volume of the IL + IR (5 Gy) treated tumors during the initial 6 days posttreatment; all other treatment groups exhibited exponential growth curves after day 3. The IL + IR (5 Gy) treatment resulted in a 5.1-day tumor growth delay compared to untreated controls. Conclusions. These findings indicate that preferential targeting of antivascular drugs to irradiated tumors results in significant tumor growth delay.

Original languageEnglish (US)
Pages (from-to)1117-1120
Number of pages4
JournalPharmaceutical Research
Volume22
Issue number7
DOIs
StatePublished - Jul 1 2005

Fingerprint

Drug Delivery Systems
Tumors
Growth
Pharmaceutical Preparations
Radiation Dosage
Neoplasms
Liposomes
Bearings (structural)
Experimental Melanomas
Inbred C57BL Mouse
Integrins
combretastatin
Melanoma
Therapeutics
Infrared radiation
Radiation

All Science Journal Classification (ASJC) codes

  • Biotechnology
  • Molecular Medicine
  • Pharmacology
  • Pharmaceutical Science
  • Organic Chemistry
  • Pharmacology (medical)

Cite this

Targeting of the antivascular drug combretastatin to irradiated tumors results in tumor growth delay. / Pattillo, Christopher B.; Sari-Sarraf, Farid; Nallamothu, Ramakrishna; Moore, Bob; Wood, George C.; Kiani, Mohammad F.

In: Pharmaceutical Research, Vol. 22, No. 7, 01.07.2005, p. 1117-1120.

Research output: Contribution to journalArticle

Pattillo, Christopher B. ; Sari-Sarraf, Farid ; Nallamothu, Ramakrishna ; Moore, Bob ; Wood, George C. ; Kiani, Mohammad F. / Targeting of the antivascular drug combretastatin to irradiated tumors results in tumor growth delay. In: Pharmaceutical Research. 2005 ; Vol. 22, No. 7. pp. 1117-1120.
@article{fd6d35ba733441a68e8e2731b18a4018,
title = "Targeting of the antivascular drug combretastatin to irradiated tumors results in tumor growth delay",
abstract = "Purpose. The aim of the study is to evaluate the effects of targeting the antivascular drug combretastatin to irradiated mouse melanomas. Methods. Combretastatin was incorporated into liposomes with surfaces modified by the addition of cyclo(Arg-Gly-Asp-d-Phe-Cys) (RGD) to create an immunoliposome (IL). This addition of RGD allows the liposome to be preferentially targeted to αvβ3, an integrin up-regulated in the vasculature of irradiated tumors. C57BL mice bearing a transplanted B16-F10 melanoma were randomly assigned to one of the following treatment groups: untreated, a single dose of 5-Gy radiation (IR), IL (14.5 mg/kg of combretastatin), 5-Gy radiation plus IL, and a systemic administration of free drug (81.0 mg/kg of combretastatin). Results. In this transplanted tumor model, there was no significant increase in the volume of the IL + IR (5 Gy) treated tumors during the initial 6 days posttreatment; all other treatment groups exhibited exponential growth curves after day 3. The IL + IR (5 Gy) treatment resulted in a 5.1-day tumor growth delay compared to untreated controls. Conclusions. These findings indicate that preferential targeting of antivascular drugs to irradiated tumors results in significant tumor growth delay.",
author = "Pattillo, {Christopher B.} and Farid Sari-Sarraf and Ramakrishna Nallamothu and Bob Moore and Wood, {George C.} and Kiani, {Mohammad F.}",
year = "2005",
month = "7",
day = "1",
doi = "10.1007/s11095-005-5646-0",
language = "English (US)",
volume = "22",
pages = "1117--1120",
journal = "Pharmaceutical Research",
issn = "0724-8741",
publisher = "Springer New York",
number = "7",

}

TY - JOUR

T1 - Targeting of the antivascular drug combretastatin to irradiated tumors results in tumor growth delay

AU - Pattillo, Christopher B.

AU - Sari-Sarraf, Farid

AU - Nallamothu, Ramakrishna

AU - Moore, Bob

AU - Wood, George C.

AU - Kiani, Mohammad F.

PY - 2005/7/1

Y1 - 2005/7/1

N2 - Purpose. The aim of the study is to evaluate the effects of targeting the antivascular drug combretastatin to irradiated mouse melanomas. Methods. Combretastatin was incorporated into liposomes with surfaces modified by the addition of cyclo(Arg-Gly-Asp-d-Phe-Cys) (RGD) to create an immunoliposome (IL). This addition of RGD allows the liposome to be preferentially targeted to αvβ3, an integrin up-regulated in the vasculature of irradiated tumors. C57BL mice bearing a transplanted B16-F10 melanoma were randomly assigned to one of the following treatment groups: untreated, a single dose of 5-Gy radiation (IR), IL (14.5 mg/kg of combretastatin), 5-Gy radiation plus IL, and a systemic administration of free drug (81.0 mg/kg of combretastatin). Results. In this transplanted tumor model, there was no significant increase in the volume of the IL + IR (5 Gy) treated tumors during the initial 6 days posttreatment; all other treatment groups exhibited exponential growth curves after day 3. The IL + IR (5 Gy) treatment resulted in a 5.1-day tumor growth delay compared to untreated controls. Conclusions. These findings indicate that preferential targeting of antivascular drugs to irradiated tumors results in significant tumor growth delay.

AB - Purpose. The aim of the study is to evaluate the effects of targeting the antivascular drug combretastatin to irradiated mouse melanomas. Methods. Combretastatin was incorporated into liposomes with surfaces modified by the addition of cyclo(Arg-Gly-Asp-d-Phe-Cys) (RGD) to create an immunoliposome (IL). This addition of RGD allows the liposome to be preferentially targeted to αvβ3, an integrin up-regulated in the vasculature of irradiated tumors. C57BL mice bearing a transplanted B16-F10 melanoma were randomly assigned to one of the following treatment groups: untreated, a single dose of 5-Gy radiation (IR), IL (14.5 mg/kg of combretastatin), 5-Gy radiation plus IL, and a systemic administration of free drug (81.0 mg/kg of combretastatin). Results. In this transplanted tumor model, there was no significant increase in the volume of the IL + IR (5 Gy) treated tumors during the initial 6 days posttreatment; all other treatment groups exhibited exponential growth curves after day 3. The IL + IR (5 Gy) treatment resulted in a 5.1-day tumor growth delay compared to untreated controls. Conclusions. These findings indicate that preferential targeting of antivascular drugs to irradiated tumors results in significant tumor growth delay.

UR - http://www.scopus.com/inward/record.url?scp=23744495032&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=23744495032&partnerID=8YFLogxK

U2 - 10.1007/s11095-005-5646-0

DO - 10.1007/s11095-005-5646-0

M3 - Article

VL - 22

SP - 1117

EP - 1120

JO - Pharmaceutical Research

JF - Pharmaceutical Research

SN - 0724-8741

IS - 7

ER -